BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

Por Rustad, E H, Dai, H Y, Hov, H, Coward, E, Beisvag, V, Myklebost, O, Hovig, E, Nakken, S, Vodák, D, Meza-Zepeda, L A, Sandvik, A K, Wader, K F, Misund, K, Sundan, A, Aarset, H, Waage, A
Publicado no Blood Cancer J (2015)